Research programme: PI3K and MAPK inhibitors - AEterna Zentaris

Drug Profile

Research programme: PI3K and MAPK inhibitors - AEterna Zentaris

Alternative Names: AEZS-126; AEZS-129; AEZS-129-136; AEZS-131; AEZS-132; AEZS-134; AEZS-136; AEZS-136 PI3K/Erk dual inhibitor - Aeterna Zentaris; AEZS-140; D-106669; D-87503

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AEterna Zentaris Inc
  • Class 2 ring heterocyclic compounds; Pyrazines; Pyridines; Pyridones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Solid tumours

Most Recent Events

  • 04 Aug 2015 AEZS-140 and back-up compounds are available for licensing as of 29 Jul 2015.
  • 08 Apr 2014 Pharmacodynamics data from a preclinical trial in tumour presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
  • 01 Apr 2014 Preclinical development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top